Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.

Curr Pharm Des · 2013 · PMC3782695 · PMID 23448440

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

High variability was found and a borderline significant reduction of 5% versus baseline was observed when results were analyzed collectively, in all patients (n=20).

also in 11,409 other papers

a clear trendno p-value reported

These changes were also supported by a clear trend towards the improvement of other markers such as adiponectin, IL-18 and soluble intercellular adhesion molecule type 1 (sICAM-1).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.